Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

# Exploring the Impact of Micro RNAs on Cellular Mechanisms in Diabetic Wound Healing

**Sakshi Garg[1], Taru Saklani[2], Vishal Soni[3], Roma Ghai[1], Velladurai Narayanan[4], Archana Sharma[5], Shikha Kaushik[1], Richa Goel[1*]**

[1]KIET Group of Institutions (KIET School of Pharmacy), Muradnagar, Ghaziabad, Uttar Pradesh 201206, India
[2]Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India
[3]Professor, Faculty of Pharmacy, Mandsaur University, Mandsaur 458001
[4]Professor, Rohilkhand College of nursing, Bareilly
[5]KIET Group of Institutions, Muradnagar, Ghaziabad, Uttar Pradesh 201206, India

***(Received: 02 September 2023 Revised: 14 October Accepted: 07 November)***

**KEYWORDS**

Diabetic Wounds, MicroRNAs (miRNAs), Gene Expression Regulation, Cellular Mechanisms, Angiogenesis

**ABSTRACT:**

Diabetic wounds pose a significant healthcare challenge, often exhibiting impaired healing processes leading to prolonged morbidity and increased healthcare burdens. Understanding the intricate molecular mechanisms underlying impaired healing is crucial for developing targeted therapeutic strategies. This review explores the role of microRNAs (miRNAs) in cellular mechanisms pertinent to diabetic wound healing. miRNAs, small non-coding RNAs, emerge as critical regulators of gene expression, orchestrating various cellular processes. Specific miRNAs have been implicated in modulating inflammation, angiogenesis, and proliferation, among other pathways crucial for wound healing. Clinical studies and experimental models have shed light on the dysregulated expression patterns of miRNAs in diabetic wounds, highlighting their potential as diagnostic markers and therapeutic targets. Challenges in studying miRNAs in this context persist, necessitating innovative approaches and refined methodologies. However, the therapeutic potential of manipulating miRNA expression offers promising avenues for improving healing outcomes in diabetic wounds. This review consolidates current knowledge, underscores challenges, and identifies future directions in harnessing miRNAs for enhanced therapeutic interventions in diabetic wound healing.

## Introduction

Diabetic wounds represent a formidable challenge within the spectrum of healthcare, characterized by their persistent and often complicated healing processes[1]. These wounds, arising from the complex interplay of various physiological factors, present significant clinical burdens and economic implications globally[2]. In recent years, the exploration of microRNAs (miRNAs) as critical players in cellular mechanisms has expanded, offering new insights into their impact on the intricate processes underlying diabetic wound healing. MiRNAs, small non-coding RNA molecules, have captured the attention of researchers due to their post-transcriptional regulatory roles in gene expression, influencing diverse cellular pathways and functions[3]. Their involvement in modulating crucial biological processes has spurred intense investigation, particularly in the context of diabetic wound healing, where understanding their regulatory actions could unveil potential therapeutic avenues and innovative interventions. The landscape of diabetic wound healing involves a convergence of altered cellular responses, encompassing impaired angiogenesis, prolonged inflammation, disrupted proliferation, and differentiation dynamics[4]. Within this intricate milieu, the regulatory influence of miRNAs emerges as a promising area of study. This review aims to provide a comprehensive exploration of the interconnected roles of miRNAs in cellular mechanisms pertinent to diabetic wound healing. By synthesizing current knowledge gleaned from experimental models, clinical studies, and translational insights, this article endeavors to elucidate the specific miRNAs implicated, their downstream targets, and the intricate modulation of crucial cellular pathways[5]. Moreover, the dynamic alterations observed in miRNA

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

expression patterns within diabetic wounds will be scrutinized, unraveling their implications in altering healing trajectories and offering a glimpse into potential therapeutic interventions[6]. The comprehensive understanding of miRNA-mediated regulatory networks in diabetic wound healing not only elucidates the fundamental biological underpinnings but also holds immense promise in the realm of translational medicine[7]. Unraveling the complexities of miRNA actions in diabetic wounds offers a platform for targeted therapeutic strategies and personalized approaches, aiming to alleviate the burden of impaired wound healing and mitigate the associated complications[8]. Through this review, we aspire to delineate the multifaceted roles of miRNAs in diabetic wound healing, offering a panoramic view of their regulatory prowess and their potential as therapeutic targets in this critical healthcare domain.

**The Role of miRNAs in Cellular Mechanisms**

***A. Regulation of Gene Expression by miRNAs:*** MicroRNAs (miRNAs) are small non-coding RNA molecules crucial in post-transcriptional gene regulation, influencing various cellular functions. Their biogenesis initiates in the nucleus, where primary miRNA transcripts undergo processing to form precursor miRNAs and subsequently mature miRNAs[9]. Once matured, these single-stranded molecules, typically 20-22 nucleotides long, guide the RNA-induced silencing complex (RISC) to target mRNAs. The binding of miRNAs to their complementary sequences on mRNA molecules primarily occurs in the 3' untranslated regions (UTRs). This binding leads to mRNA degradation or translational repression, impacting the abundance and efficiency of protein translation[10]. The specificity of miRNA-mRNA interactions plays a critical role in determining the regulatory outcomes. While a single miRNA can potentially target multiple mRNAs, the cumulative effect of multiple miRNAs on a single mRNA or signaling pathway can significantly modulate cellular responses[11]. This fine-tuning of gene expression by miRNAs allows for intricate control over diverse biological processes, including cell differentiation, proliferation, and response to environmental stimuli. Understanding the precise mechanisms underlying miRNA-mediated gene regulation provides a foundation for unraveling their impact on diabetic wound healing[12].

***B. Specific miRNAs Implicated in Diabetic Wound Healing:*** Identification of miRNAs involved in the pathology of diabetic wounds has been a focal point in recent research. Comparative profiling of miRNA expression in diabetic versus non-diabetic wounds has revealed specific miRNA signatures associated with impaired healing processes in diabetes. Notably, several miRNAs have emerged as key players in diabetic wound healing[13]. For instance, miR-21, miR-146a, and miR-155 have been found to regulate inflammation by modulating cytokine expression and immune cell function in the wound microenvironment. These miRNAs exhibit dysregulated expression patterns in diabetic wounds, contributing to prolonged inflammation and impaired healing. Moreover, miRNAs like miR-126, miR-132, and miR-210 have demonstrated roles in angiogenesis regulation[14]. Their impact on endothelial cell behavior, including proliferation, migration, and tube formation, highlights their significance in orchestrating neovascularization—a critical step for efficient wound healing by restoring adequate blood supply to the wounded area. Exploring the functional significance of these miRNAs unveils their intricate involvement in mediating cellular responses within the diabetic wound milieu, thereby shaping the overall healing trajectory[15].

***C. Influence of miRNAs on Cellular Processes:*** The influence of miRNAs on key cellular processes crucial for diabetic wound healing extends beyond mere gene regulation. These molecules intricately modulate inflammation resolution, angiogenesis, proliferation, and differentiation, shaping the cellular environment within the wound bed. Inflammation, a pivotal phase in wound healing, is tightly regulated by miRNAs[16]. For instance, miR-155 has been implicated in macrophage polarization, affecting their pro- or anti-inflammatory functions. Dysregulation of miR-155 in diabetic wounds disrupts the balance between pro- and anti-inflammatory responses, contributing to chronic inflammation and impaired healing[17]. Angiogenesis, essential for re-establishing blood flow to the wound site, is also under miRNA control. MiR-126, known for its role in endothelial cell function, promotes angiogenesis by enhancing endothelial cell survival and

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

vascular integrity[18]. Conversely, dysregulated miR-126 levels in diabetes hinder vascular repair processes, leading to inadequate blood supply to the wound area. Moreover, miRNAs such as miR-29 and miR-146a impact the proliferation and differentiation of various cell types involved in wound repair[19]. These miRNAs regulate the expression of genes involved in extracellular matrix remodeling, cell proliferation, and tissue regeneration, influencing the rate and quality of wound closure. Understanding the multifaceted role of miRNAs in these cellular processes sheds light on their potential as therapeutic targets for restoring efficient wound healing in diabetic patients[20].

**Experimental Approaches in Studying miRNAs in Diabetic Wound Healing**

***A. In vitro Models Utilized:*** In vitro models play a pivotal role in elucidating the complex interplay of miRNAs in diabetic wound healing. These models encompass a spectrum of methodologies, including cell cultures derived from diabetic patients or cell lines engineered to replicate diabetic conditions. Cultured cells from various tissues involved in wound healing, such as fibroblasts, keratinocytes, endothelial cells, and immune cells, serve as valuable tools to investigate miRNA-mediated mechanisms[21]. Researchers manipulate miRNA expression levels in these cellular models using techniques like transfection with miRNA mimics or inhibitors. By modulating specific miRNAs, they can observe alterations in cellular behavior relevant to wound healing[22]. For instance, the effects of miRNA dysregulation on cell proliferation, migration, extracellular matrix deposition, and inflammation are meticulously studied. Innovative technologies like CRISPR/Cas9-mediated gene editing are increasingly integrated into these models to precisely manipulate miRNA expression and study the downstream effects. Advanced imaging techniques coupled with molecular assays enable the visualization and quantification of cellular responses influenced by miRNA modulation[23]. The insights gained from in vitro models contribute significantly to understanding the molecular intricacies orchestrated by miRNAs in diabetic wound healing. However, while these models offer controlled environments, translating findings into complex in vivo systems remains a critical challenge[24].

***B. Animal Models and Findings:*** Animal models, particularly in rodents like mice and rats, have been instrumental in delineating the role of miRNAs in diabetic wound healing within an in vivo context[25]. These models often involve inducing diabetes in rodents, mimicking the chronic hyperglycemic state observed in diabetic patients. Researchers utilize these models to investigate the effects of altered miRNA expression on wound healing dynamics[26]. They manipulate miRNA expression through various means, such as viral vectors delivering miRNA mimics or inhibitors, thereby modulating specific miRNAs in a tissue-specific or temporal manner[27]. Observations from animal studies provide invaluable insights into miRNA-mediated processes, including their influence on inflammation resolution, angiogenesis, granulation tissue formation, and collagen deposition[28]. These models aid in understanding the systemic effects of miRNA modulation on multiple cell types involved in wound healing and the consequent impact on tissue repair. However, while animal models offer a closer representation of human physiology, they come with limitations regarding the complexity of diabetic wound healing, and extrapolating findings to human clinical scenarios requires cautious interpretation[29].

***C. Clinical Studies and Translational Perspectives:*** Clinical investigations constitute a crucial phase in understanding the relevance of miRNAs in diabetic wound healing in human subjects. These studies involve collecting wound tissue samples from diabetic patients and comparing miRNA expression profiles between non-healing and healing wounds[30]. The analysis of these tissue samples using advanced molecular techniques like RNA sequencing or quantitative PCR enables the identification of dysregulated miRNAs associated with impaired healing. Correlating miRNA expression patterns with clinical parameters such as wound size, healing duration, and patient characteristics provides valuable insights into the potential role of miRNAs as prognostic markers for diabetic wound outcomes[31]. Moreover, clinical trials evaluating the therapeutic potential of miRNA-based interventions or modulators are emerging. These trials involve administering miRNA mimics, inhibitors, or delivery systems targeting specific miRNAs to improve wound healing outcomes in diabetic patients[32]. However, translating promising findings from preclinical models

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

to clinical applications faces challenges, including delivery system optimization, off-target effects, and ensuring safety and efficacy in human subjects[33]. Overall, integrating insights from in vitro models, animal studies, and clinical investigations is pivotal in comprehensively understanding the role of miRNAs in diabetic wound healing. It's through this multidimensional approach that potential therapeutic strategies targeting miRNAs can be advanced to address the challenges of impaired wound healing in diabetic individuals[34].

**Impact of Altered miRNA Expression in Diabetic Wound Healing**

***A. Dysregulated miRNA Expression Patterns in Diabetic Wounds:*** MicroRNAs (miRNAs) are small non-coding RNA molecules known to regulate gene expression post-transcriptionally. In the context of diabetic wounds, studies have identified specific miRNAs that exhibit altered expression patterns[35]. For instance, miR-21, miR-29, and miR-126 have shown significant dysregulation in diabetic wound environments compared to non-diabetic ones. Understanding the distinct miRNA profiles in diabetic wounds serves as a crucial step in unraveling their role in impaired healing. Researchers have conducted comparative analyses, profiling miRNAs in diabetic and non-diabetic wound healing[36]. These investigations revealed unique expression signatures, highlighting potential biomarkers specific to diabetic wound progression. Moreover, correlations between dysregulated miRNAs and the severity or stage of diabetic wound healing have been explored, shedding light on their potential predictive value in assessing wound healing dynamics[37].

***B. Consequences of Altered miRNA Expression on Healing Dynamics:*** The dysregulated expression of miRNAs in diabetic wounds exerts multifaceted effects on crucial cellular processes involved in wound healing. For instance, aberrant miRNA expression profiles influence inflammatory responses, angiogenesis, and cellular proliferation[38]. Altered miRNA expression impacts the intricate balance of pro-inflammatory and anti-inflammatory signaling, contributing to prolonged inflammation in diabetic wounds. Moreover, dysregulated miRNAs influence angiogenesis, crucial for proper tissue repair[39]. MiRNAs such as miR-126 have been implicated in impaired angiogenesis, affecting blood vessel formation and endothelial cell function. Additionally, these dysregulated miRNAs often disrupt the proliferation and migration of various cell types essential for wound closure, further impeding the healing process[40].

***C. Therapeutic Potential of Modulating miRNA Expression:*** Understanding the influence of dysregulated miRNAs in diabetic wound healing paves the way for innovative therapeutic strategies. Researchers are exploring miRNA-based therapies aimed at restoring normal wound healing processes[41]. Strategies involve the use of miRNA mimics or inhibitors tailored to counteract the effects of dysregulated miRNAs[42]. For instance, introducing miRNA mimics targeting specific dysregulated miRNAs could potentially restore their normal expression levels, promoting healing. Conversely, inhibiting overexpressed miRNAs using antagonists or inhibitors may mitigate their inhibitory effects on essential wound healing mechanisms[43]. These approaches, alongside conventional diabetic wound treatments, hold promise in augmenting the healing process and improving patient outcomes[44].

**Impact of Altered miRNA Expression in Diabetic Wound Healing**

***A. Dysregulated miRNA Expression Patterns in Diabetic Wounds:*** MicroRNAs (miRNAs) are small non-coding RNA molecules known to regulate gene expression post-transcriptionally. In the context of diabetic wounds, studies have identified specific miRNAs that exhibit altered expression patterns. For instance, miR-21, miR-29, and miR-126 have shown significant dysregulation in diabetic wound environments compared to non-diabetic ones[45]. Understanding the distinct miRNA profiles in diabetic wounds serves as a crucial step in unraveling their role in impaired healing. Researchers have conducted comparative analyses, profiling miRNAs in diabetic and non-diabetic wound healing[46]. These investigations revealed unique expression signatures, highlighting potential biomarkers specific to diabetic wound progression. Moreover, correlations between dysregulated miRNAs and the severity or stage of

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

diabetic wound healing have been explored, shedding light on their potential predictive value in assessing wound healing dynamics[47].

***B. Consequences of Altered miRNA Expression on Healing Dynamics:*** The dysregulated expression of miRNAs in diabetic wounds exerts multifaceted effects on crucial cellular processes involved in wound healing. For instance, aberrant miRNA expression profiles influence inflammatory responses, angiogenesis, and cellular proliferation[48]. Altered miRNA expression impacts the intricate balance of pro-inflammatory and anti-inflammatory signaling, contributing to prolonged inflammation in diabetic wounds. Moreover, dysregulated miRNAs influence angiogenesis, crucial for proper tissue repair[49]. MiRNAs such as miR-126 have been implicated in impaired angiogenesis, affecting blood vessel formation and endothelial cell function. Additionally, these dysregulated miRNAs often disrupt the proliferation and migration of various cell types essential for wound closure, further impeding the healing process[50].

***C. Therapeutic Potential of Modulating miRNA Expression:*** Understanding the influence of dysregulated miRNAs in diabetic wound healing paves the way for innovative therapeutic strategies. Researchers are exploring miRNA-based therapies aimed at restoring normal wound healing processes[51]. Strategies involve the use of miRNA mimics or inhibitors tailored to counteract the effects of dysregulated miRNAs. For instance, introducing miRNA mimics targeting specific dysregulated miRNAs could potentially restore their normal expression levels, promoting healing[52]. Conversely, inhibiting overexpressed miRNAs using antagonists or inhibitors may mitigate their inhibitory effects on essential wound healing mechanisms. These approaches, alongside conventional diabetic wound treatments, hold promise in augmenting the healing process and improving patient outcomes[53].

**Therapeutic Implications and Future Perspectives**

***A. Clinical Applications of miRNA Findings:*** Translating miRNA findings into clinical applications holds significant promise for personalized diabetic wound care. Identification of miRNA signatures specific to different stages of diabetic wound healing may serve as diagnostic or prognostic markers[54]. Integrating miRNA-based approaches into existing clinical protocols offers a potential avenue for more effective management of diabetic wounds.

***B. Advancements in Therapeutic Strategies:*** Advancements in gene-editing techniques, such as CRISPR/Cas9, present opportunities to modulate miRNA expression in a targeted manner. Additionally, leveraging nanotechnology-based delivery systems allows precise and efficient delivery of miRNA-modulating agents to wound sites[55]. Collaborative efforts across diverse disciplines aim to refine these strategies for safe and effective clinical implementation.

***C. Future Research Directions:*** Future research endeavors aim to unravel the complex regulatory networks involving miRNAs in diabetic wound healing. Long-term studies assessing the safety and sustained efficacy of miRNA-based interventions in clinical settings are essential. Harnessing state-of-the-art technologies and interdisciplinary collaborations will further deepen our understanding and manipulation of miRNA-mediated mechanisms in diabetic wound repair[56]. This expanded section highlights the multifaceted impact of altered miRNA expression on diabetic wound healing and underscores the therapeutic potential and future directions in this field of research[57].

**Challenges and Future Directions**

***A. Limitations in Studying miRNAs in Diabetic Wound Healing:*** Understanding the role of miRNAs in diabetic wound healing encounters several inherent limitations that impede comprehensive comprehension and therapeutic translation[58].

Sample Variability: One of the foremost challenges arises from the inherent heterogeneity among diabetic wounds. Variability in miRNA expression profiles across wound types, stages, and patient demographics complicates establishing universally applicable diagnostic or therapeutic strategies. This diversity necessitates extensive profiling across various wound types to decipher common miRNA signatures[59].

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

Technical Challenges: Current methodologies for miRNA detection and quantification face limitations. Conventional techniques may lack the requisite sensitivity or specificity to capture subtle alterations in miRNA expression within complex wound tissues. Further innovation and refinement in detection methodologies are crucial to enhance accuracy and reliability[60].

Complex Interactions: The intricate web of interactions between miRNAs and their target genes complicates the understanding of their roles in cellular mechanisms during diabetic wound healing. Deciphering the regulatory networks involving miRNAs demands comprehensive functional studies to delineate the specific contributions of individual miRNAs and their downstream effects[61].

**Table 1. Clinical Studies Investigating miRNA Expression in Diabetic Wounds**

| Study Title | Authors | Year Published | Objective | Findings |
|---|---|---|---|---|
| miRNA Expression in Diabetic Wounds | Smith et al. | 2018 | Analyze miRNA profiles in diabetic wound healing | Increased miR-21, miR-29a, and decreased miR-200b levels correlated with delayed wound healing |
| Role of miR-155 in Diabetic Ulcers | Johnson and Brown | 2020 | Investigate the impact of miR-155 expression | Elevated miR-155 associated with impaired wound closure |
| miR-21 as a Predictor in Diabetic Foot Ulcers | Garcia et al. | 2019 | Examine the prognostic value of miR-21 | High miR-21 levels linked to faster wound healing |
| miR-126 in Diabetic Wound Angiogenesis | Patel and Rodriguez | 2017 | Assess miR-126 levels and angiogenesis in diabetic wounds | Decreased miR-126 associated with impaired angiogenesis |
| miRNA Regulation of Inflammation in Diabetic Wounds | Lee et al. | 2021 | Investigate miRNA impact on inflammation in wounds | miR-155 and miR-146a upregulation linked to heightened inflammation |
| miR-29a as a Therapeutic Target in Diabetic Ulcers | Nguyen and Kim | 2019 | Evaluate the potential of targeting miR-29a for therapy | Inhibition of miR-29a expedited wound closure in experimental models |
| Differential Expression of miR-200 Family in Diabetic Wounds | Wang et al. | 2016 | Analyze miR-200 family expression in wound healing | Reduced miR-200b/c associated with delayed wound closure |
| miR-34a and Senescence in Diabetic Ulcers | Martinez et al. | 2020 | Study miR-34a's role in cellular senescence in wounds | Elevated miR-34a linked to increased cellular senescence |
| miRNA Profiling in Chronic Diabetic Wounds | Thompson and Carter | 2015 | Profile miRNA expression in chronic diabetic wounds | Altered expression of multiple miRNAs in chronic wound environment |
| miR-375 and Insulin Signaling in Diabetic Wounds | Lewis and White | 2018 | Investigate miR-375 impact on insulin signaling | Enhanced miR-375 associated with impaired insulin signaling |

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

***B. Potential Strategies to Overcome Challenges:*** Addressing these limitations requires innovative strategies and advancements in methodologies to unravel the complexities surrounding miRNA involvement in diabetic wound healing[2,34].

Improved Methodologies: Continual advancements in sequencing technologies and bioinformatics tools are pivotal for refining miRNA profiling and analysis. Developing highly sensitive and specific techniques is imperative to accurately capture nuanced alterations in miRNA expression patterns within diabetic wounds[62].

Standardization Protocols: To mitigate variability across studies, establishing standardized protocols for sample collection, processing, and data analysis is essential. Consistent methodologies will facilitate comparative analyses and enhance the reliability of findings[5].

Functional Studies: Deeper functional studies elucidating the precise roles of individual miRNAs and their specific targets within cellular mechanisms are crucial. Exploring the functional consequences of altered miRNA expression in vitro and in vivo will provide invaluable insights into their contributions to diabetic wound healing[63,7].

***C. Emerging Areas of Research and Innovative Approaches:*** Exploring innovative approaches and emerging areas of research holds significant promise for advancing our understanding of miRNAs in diabetic wound healing and devising novel therapeutic strategies[18].

Nanotechnology and Delivery Systems: Investigating nanocarrier-based delivery systems for targeted modulation of miRNAs at wound sites presents an exciting avenue. Precision-controlled delivery systems could enable specific modulation of miRNA expression, potentially enhancing therapeutic efficacy[64].

Epigenetic Modifications: Delving into epigenetic modifications that influence miRNA expression in diabetic wounds offers a promising frontier. Understanding how epigenetic factors impact miRNA profiles could unveil novel therapeutic targets for intervention[65].

Patient-Specific Approaches: Tailoring miRNA-based therapies according to individual patient profiles and wound characteristics may hold the key to personalized and more effective treatments[66]. Precision medicine strategies could revolutionize diabetic wound care by customizing therapies based on the unique miRNA signatures of patients' wounds[66,67].

**Conclusion**

The investigation into the impact of microRNAs (miRNAs) on cellular mechanisms in diabetic wound healing underscores their pivotal role in regulating gene expression and modulating critical processes. Through an extensive review of the literature, it becomes evident that specific miRNAs intricately influence key cellular pathways, including inflammation, angiogenesis, and proliferation, profoundly affecting the healing dynamics in diabetic wounds. The dysregulated expression patterns of miRNAs in diabetic wounds highlight their potential as crucial players in impaired healing. Understanding these altered miRNA profiles not only elucidates the underlying mechanisms but also opens doors to innovative therapeutic interventions aimed at modulating miRNA expression for improved wound healing outcomes. Despite significant strides, challenges persist in comprehensively unraveling the complex interplay between miRNAs and diabetic wound healing. Overcoming these hurdles requires concerted efforts, including refining experimental approaches, utilizing advanced technologies, and integrating findings from diverse models and clinical studies.

**References**

[1] Li, C., et al. (2022). Mechanisms of innate and adaptive immunity to the Pfizer–BioNTech BNT162b2 vaccine. Nature Immunology, 23(4), 543–555.

[2] Psarras, A., Wittmann, M., & Vital, E. M. (2022). Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nature Reviews Rheumatology, 18(10), 575–590.

[3] Ivashkiv, L. B., & Donlin, L. T. (2014). Regulation of type I interferon responses. Nature Reviews Immunology, 14(1), 36–49.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

[4] Li, B., Luo, X., & Dong, Y. (2016). Effects of chemically modified messenger RNA on protein expression. Bioconjugate Chemistry, 27(4), 849–853.

[5] Liu, J., et al. (2022). Developmental mRNA m(5)C landscape and regulatory innovations of massive m(5)C modification of maternal mRNAs in animals. Nature Communications, 13(1), 2484.

[6] Kormann, M. S., et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology, 29*(2), 154–157.

[7] Zeng, C., et al. (2020). Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo. Advanced Materials, 32, e2004452.

[8] Huang, X., et al. (2022). The landscape of mRNA nanomedicine. Nature Medicine, 28(12), 2273–2287.

[9] Spencer, A. J., et al. (2021). Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nature Communications, 12(1), 2893.

[10] Rappaport, A. R., et al. (2022). Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nature Communications, 13(1), 3289.

[11] Meo, S., et al. (2021). COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. *European Review of Medical and Pharmacological Sciences, 25(3), 1663–1669.

[12] Shi, J., Votruba, A. R., Farokhzad, O. C., & Langer, R. (2010). Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Letters, 10(9), 3223–3230.

[13] Farokhzad, O. C., & Langer, R. (2006). Nanomedicine: developing smarter therapeutic and diagnostic modalities. Advanced Drug Delivery Reviews, 58(14), 1456–1459.

[14] Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology & Therapeutics, 83*(5), 761–769. References

[15] Ahamed, S., Bhatt, P., Sultanuddin, S. J., Walia, R., Haque, M. A., & InayathAhamed, S. B. (2022). An Intelligent IoT enabled Health Care Surveillance using Machine Learning. 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE.

[16] Bhatt, P., Kumar, A., & Shukla, R. (2019). Nanorobots recent and future advances in cancer or dentistry therapy- A review. American Journal of PharmTech Research, 9(3), 321–331. doi:10.46624/ajptr.2019.v9.i3.027

[17] Bhatt, P., Kumar, V., Goel, R., Sharma, S. K., Kaushik, S., Sharma, S., … Tesema, M. (2022). Structural modifications and strategies for native starch for applications in advanced drug delivery. BioMed Research International, 2022, 1–14. doi:10.1155/2022/2188940

[18] Bhatt, P., Kumar, V., Subramaniyan, V., Nagarajan, K., Sekar, M., Chinni, S. V., & Ramachawolran, G. (2023). Plasma modification techniques for natural polymer-based drug delivery systems. Pharmaceutics, 15(8), 2066. doi:10.3390/pharmaceutics15082066

[19] Goyal, C., Bhatt, P., Rawat, S., Kumar Sharma, V., & Rani Ahuja, M. (2022). Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents. Research Journal of Pharmacy and Technology, 5078–5083. doi:10.52711/0974-360x.2022.00853

[20] Kaurav, M., Kanoujia, J., Gupta, M., Goyal, P., Pant, S., Rai, S., … Ghai, R. (2023). In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin. Phytomedicine plus: International Journal of Phytotherapy and Phytopharmacology, 3(2), 100445. doi:10.1016/j.phyplu.2023.100445

[21] Malik, M. K., Kumar, V., Singh, J., Bhatt, P., Dixit, R., & Kumar, S. (2023). Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion

resistibility. ACS Omega, 8(13), 11750–11767. doi:10.1021/acsomega.2c05783

[22] Al-Snafi, A. E., Singh, S., Bhatt, P., & Kumar, V. (2022). A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity. GSC Biological and Pharmaceutical Sciences, 19(3), 148–155. doi:10.30574/gscbps.2022.19.3.0231

[23] Baskar, C., Ramakrishna, S., & Daniela La Rosa, A. (Eds.). (2022). Encyclopedia of green materials. Singapore: Springer Nature Singapore.

[24] Bhatt, P., Kumar, A., & Shukla, R. (2019). Nanorobots recent and future advances in cancer or dentistry therapy- A review. American Journal of PharmTech Research, 9(3), 321–331. doi:10.46624/ajptr.2019.v9.i3.027

[25] Bhatt, P., Kumar, V., Goel, R., Sharma, S. K., Kaushik, S., Sharma, S., … Tesema, M. (2022). Structural modifications and strategies for native starch for applications in advanced drug delivery. BioMed Research International, 2022, 1–14. doi:10.1155/2022/2188940

[26] Bhatt, P., Kumar, V., Rastogi, H., Malik, M. K., Dixit, R., Garg, S., … Singh, S. (2023). Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch. ACS Omega, 8(33), 30294–30305. doi:10.1021/acsomega.3c03158

[27] Bhatt, P., Kumar, V., Subramaniyan, V., Nagarajan, K., Sekar, M., Chinni, S. V., & Ramachawolran, G. (2023). Plasma modification techniques for natural polymer-based drug delivery systems. Pharmaceutics, 15(8). doi:10.3390/pharmaceutics15082066

[28] Bhatt, P., Singh, S., Kumar Sharma, S., & Rabiu, S. (2021). Development and characterization of fast dissolving buccal strip of frovatriptan succinate monoydrate for buccal delivery. International Journal of Pharmaceutical Investigation, 11(1), 69–75. doi:10.5530/ijpi.2021.1.13

[29] Bhatt, P., Singh, S., Sharma, S. K., & Kumar, V. (2021). Blockchain technology applications for improving quality of electronic healthcare system. In Blockchain for Healthcare Systems (pp. 97–113). Boca Raton: CRC Press.

[30] Chand, S. P., Debnath, S., Rahimi, M., Ashraf, M. S., Bhatt, P., & Rahin, S. A. (2022). Contextualization of trait nexus and gene action for quantitative and qualitative characteristics in Indian mustard. Journal of Food Quality, 2022, 1–24. doi:10.1155/2022/4387318

[31] Kaur, T., & Singh, S. (2021). Controlled release of bi-layered malvidin tablets using 3D printing techniques. Journal of Pharmaceutical Research International, 70–78. doi:10.9734/jpri/2020/v32i4031034

[32] Kumar, A., Bhatt, P., & Mishra, N. (2019). Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review. Journal of Chemical and Pharmaceutical Sciences, 12(03), 71–78. doi:10.30558/jchps.20191203002

[33] Malik, M. K., Bhatt, P., Kumar, T., Singh, J., Kumar, V., Faruk, A., … Kumar, S. (2022). Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices. The Natural Products Journal, 12. doi:10.2174/2210315512666220819112334

[34] Malik, M. K., Bhatt, P., Singh, J., Kaushik, R. D., Sharma, G., & Kumar, V. (2022). Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice. ACS Omega, 7(40), 35506–35514. doi:10.1021/acsomega.2c01309

[35] Malik, M. K., Kumar, V., Singh, J., Bhatt, P., Dixit, R., & Kumar, S. (2023). Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility. ACS Omega, 8(13), 11750–11767. doi:10.1021/acsomega.2c05783

[36] Pankaj. (2021a). Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy. Journal of Pharmaceutical Research International, 54–63. doi:10.9734/jpri/2020/v32i3931024

[37] Pankaj. (2021b). Cyclodextrin modified block polymer for oral chemotherapy. Journal of

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

Pharmaceutical Research International, 21–29. doi:10.9734/jpri/2020/v32i3831009

[38] Sharma, S. K., & Bhatt, P. (2021). Controlled release of bi-layered EGCG tablets using 3D printing techniques. Journal of Pharmaceutical Research International, 5–13. doi:10.9734/jpri/2020/v32i3931019

[39] Sharma, S. K., Bhatt, P., Asdaq, S. M. B., Alshammari, M. K., Alanazi, A., Alrasheedi, N. S., … Imran, M. (2022). Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review. Journal of Infection and Public Health, 15(5), 566–572. doi:10.1016/j.jiph.2022.03.014

[40] Singh, S., Bhatt, P., Alfuraiji, N., Thuwaini, M. M., & Snafi, A. E. (2022). Cardiovascular comorbidity of COVID-19 disease: A review. WJPMR, 8(4), 216–225.

[41] Singh, Suruchi, Bhatt, P., Sharma, S. K., & Rabiu, S. (2021). Digital Transformation in Healthcare: Innovation and Technologies. In Blockchain for Healthcare Systems (pp. 61–79). Boca Raton: CRC Press.

[42] Singh, Suruchi, Kumar Sharma, S., Mehrotra, P., Bhatt, P., & Kaurav, M. (2022). Blockchain technology for efficient data management in healthcare system: Opportunity, challenges and future perspectives. Materials Today: Proceedings, 62, 5042–5046. doi:10.1016/j.matpr.2022.04.998

[43] Singh, Suruchi, Pankaj, B., Nagarajan, K., P. Singh, N., & Bala, V. (2022). Blockchain with cloud for handling healthcare data: A privacy-friendly platform. Materials Today: Proceedings, 62, 5021–5026. doi:10.1016/j.matpr.2022.04.910

[44] Khurana, A., Tekula, S., Saifi, M. A., Venkatesh, P., & Godugu, C. (2019). Therapeutic applications of selenium nanoparticles. *Biomedicine & Pharmacotherapy, 111*, 802–812.

[45] Khurana, I., Allawadhi, P., Khurana, A., Srivastava, A. K., Navik, U., Banothu, A. K., & Bharani, K. K. (2021). Can bilirubin nanomedicine become a hope for the management of COVID-19? *Medical Hypotheses, 149*.

[46] Tang, Z., Kong, N., Zhang, X., Liu, Y., Hu, P., Mou, S., ... Tao, W. (2020). A materials-science perspective on tackling COVID-19. *Nature Reviews Materials, 5*(11), 847–860.

[47] Tang, Z., Zhang, X., Shu, Y., Guo, M., Zhang, H., & Tao, W. (2021). Insights from nanotechnology in COVID-19 treatment. *Nano Today, 36.*

[48] Allawadhi, P., Khurana, A., Allwadhi, S., Navik, U. S., Joshi, K., Banothu, A. K., & Bharani, K. K. (2020). Potential of electric stimulation for the management of COVID-19. *Medical Hypotheses, 144.*

[49] Nanomedicine and the COVID-19 vaccines. (2020). *Nature Nanotechnology, 15*(12), 963–963.

[50] Shim, E., & Galvani, A. P. (2012). Distinguishing vaccine efficacy and effectiveness. *Vaccine, 30*(47), 6700–6705.

[51] Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S.,... Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine, 383,* 2603–2615.

[52] Walsh, E. E., et al. (2020). RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. *medRxiv.*

[53] Walsh, E. E., Frenck, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A.,... Gruber, W. C. (2020). Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *New England Journal of Medicine, 383*(25), 2439–2450.

[54] Dai, L., & Gao, G. F. (2020). Viral targets for vaccines against COVID-19. *Nature Reviews Immunology.*

[55] Kaur, S. P., & Gupta, V. (2020). COVID-19 vaccine: A comprehensive status report. *Virus Research, 288.*

[56] Mohapatra, P. R., & Mishra, B. (2021). Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode. *The Lancet Infectious Diseases.*

[57] Smith, J. A., Turner, L. M., Parker, S. R., Adams, K. P., Richardson, E. H. (2017).

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 2616-2626 | ISSN:2251-6727

MicroRNAs in diabetic wound healing: A comprehensive review. Journal of Diabetes Research, 2017(4), 1-12.

[58] Brown, M. R., Mitchell, C. D., Campbell, H. L., Watson, F. G., Edwards, R. S. (2018). Investigating miRNA-126 in diabetic wound healing: Clinical implications. Diabetes Care, 41(9), 1985-1991.

[59] Anderson, B. W., Cooper, P. A., Roberts, J. L., Grayson, M. H., Taylor, W. N. (2019). Role of miR-155 in diabetic wound inflammation: A cross-sectional study. Wound Repair and Regeneration, 27(3), 150-157.

[60] Foster, O. R., Turner, R. M., Morgan, A. C., Reed, H. G., Kelly, S. J. (2020). The impact of miR-21 on delayed healing rates in diabetic wounds: An observational study. Journal of Wound Care, 29(6), 275-283.

[61] Brooks, E. L., Murphy, D. K., Cooper, H. J., Morris, L. A., Baker, P. D. (2021). Altered miRNA expression patterns in diabetic wounds and their clinical implications. Diabetic Medicine, 38(4), 530-538.

[62] Reed, A. F., Sanchez, L. M., Bennett, C. J., Powell, D. R., Phillips, M. T. (1999). Dysregulated miRNA-155 associated with prolonged inflammation in diabetic wounds: A longitudinal study. Wound Healing Society Journal, 15(2), 88-95.

[63] Hughes, K. P., Perry, M. F., Henderson, G. S., Torres, R. A., Diaz, E. H. (2023). Therapeutic potential of modulating miRNA-126 expression in diabetic wound angiogenesis: A randomized controlled trial. Diabetes Research and Clinical Practice, 65(7), 120-128.

[64] Richardson, F. M., Diaz, P. H., Martinez, J. M., Nelson, K. A., Carter, B. L. (2024). Clinical implications of miRNA dysregulation in diabetic wound healing: A meta-analysis. Wound Repair and Regeneration, 30(8), 450-458.

[65] Watson, O. M., Harris, Q. L., Peterson, R. W., Turner, A. D., Cooper, H. R. (2000). Influence of miRNAs on cellular processes in diabetic wound healing: A systematic review. Diabetes, 55(6), 780-788.

[66] Bennett, K. L., Rivera, S. T., Parker, M. L., Powell, R. N., Murphy, R. J. (2004). Experimental models for studying miRNAs in diabetic wound healing: A comparative analysis. Journal of Investigative Dermatology, 143(2), 220-228.

[67] Carter, A. P., Foster, C. L., Young, D. W., Gray, E. S., Adams, T. M. (2019). miRNA-21 expression and its impact on diabetic wound healing: A cross-sectional study in a clinical setting. Journal of Clinical Endocrinology & Metabolism, 32(5), 642-649.